Clinical Trials Logo

Stomach Cancer clinical trials

View clinical trials related to Stomach Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03704077 Withdrawn - Gastric Cancer Clinical Trials

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

NCT ID: NCT03644459 Withdrawn - Colorectal Cancer Clinical Trials

Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

Start date: April 3, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers. This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

NCT ID: NCT02943603 Withdrawn - Adenocarcinoma Clinical Trials

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Start date: January 2017
Phase: Phase 2
Study type: Interventional

This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.

NCT ID: NCT02205463 Withdrawn - Esophageal Cancer Clinical Trials

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.

NCT ID: NCT00800969 Withdrawn - Adenocarcinoma Clinical Trials

Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach. Aim of the study is to evaluate the accuracy of PET-CT for the preoperative assessment of lymph node metastasis. The evaluation includes a combination with standard diagnostic tools (endoluminal ultrasound, CT and diagnostic laparoscopy prior to neoadjuvant therapy). Standardized D2-lymphadenectomy is performed and individual lymph node stations (Nr 1-12 according to the Japanese classification) are histopathologically examined. Furthermore we evaluate the role of the PET-CT for early metabolic response evaluation in patients receiving neoadjuvant chemotherapy. - Trial with surgical intervention

NCT ID: NCT00622804 Withdrawn - Stomach Cancer Clinical Trials

Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the degree of bile reflux and gastric stasis according the reconstruction methods after distal subtotal gastrectomy for gastric cancer, and to find out the proper method. We collect ninety patients who undergo distal gastrectomy for gastric cancers for this study from 5 institutions and randomly divide into 3 groups according to reconstruction methods: 1) Billroth-II (B-II), 2) Roux en Y gastrojejunostomy (RY-GJ) and 3) uncut Roux en Y gastrojejunostomy (uncut RY-GJ).